Phylogica, McComb Foundation collaborate on burns treatment
09 December, 2005 by Ruth BeranPerth-based Phylogica (ASX:PYC) and the McComb Foundation are jointly developing a potential new drug to speed up the healing process and reduce the scarring caused by burns.
Premier Bionics raises $1.25m for Israeli trauma simulator
09 December, 2005 by Helen SchullerPremier Bionics (ASX:PBI) has raised AUD$1.25 million in a placement to provide capital to accelerate the development of a mass trauma simulator in Israel.
BTF earns fast growth kudos
09 December, 2005 by Helen SchullerPrivate Sydney-based biotech BTF has achieved 101 per cent revenue growth over the last three years, earning itself a place in the 2005 Deloitte Technology Fast 50 awards.
UNSW joins Uniseed fund, commits $10m
08 December, 2005 by Ruth BeranThe University of New South Wales (UNSW) has formally joined the pre-seed commercialisation fund Uniseed with a financial commitment of AUD$10 million.
Victoria-Israel R&D fund launched
07 December, 2005 by Ruth BeranA US$6 million fund was launched today for joint Israeli-Victorian projects in areas such as biotechnology, healthcare, nanotechnology, environmental technologies and advanced manufacturing.
New CEO at CogState
07 December, 2005 by Helen SchullerFollowing the resignation of CogState chief executive officer Peter Bick, Brad O'Connor has been promoted internally from chief financial officer to the CEO role.
No holiday for Regenera shareholders as firm re-jigs merger
07 December, 2005 by Helen SchullerShareholders in Regenera (ASX:RGA) have been asked to attend a meeting in Perth between Christmas and New Year, as the company seeks to revise terms of its planned merger with US firm Advanced Ocular Systems (AOS).
New Biota CEO speaks of road ahead
07 December, 2005 by Ruth BeranOn Friday, Biota Holdings (ASX:BTA) introduced Peter Cook as its new CEO and managing director, replacing Peter Molloy. On his first day at the company, Cook spoke with Ruth Beran about his background, the future for the company and the similarities between orbital engines and biotechnology.
Domantis, Bristol-Myers Squibb form partnership
06 December, 2005 by Graeme O'NeillUK firm Domantis, 36 per cent owned by Peptech (ASX:PTD), has signed an agreement with global pharma Bristol-Myers Squibb (NYSE:BMY) to develop domain-antibody (dAb) therapeutics for multiple immunology and cancer targets.
Prima receives first payment from Arthron sale
05 December, 2005 by Ruth BeranPrima Biomed (ASX:PRR) has received the first payment of US$500,000 from Toronto-based immunology company Trillium Therapeutics following the settlement of the sale of Prima's subsidiary Arthron.
Anadis claims success with anthrax killer
05 December, 2005 by Graeme O'NeillMelbourne biopharma Anadis (ASX:ANX) has announced that antibody extracts from the colostrum of immunised dairy cows completely protects cells from the lining of the human lung against deadly anthrax toxin in vitro.
Medical Therapies closes IPO offer oversubscribed
02 December, 2005 by Helen SchullerMedical Therapies has completed its IPO capital raising over-subscribed and is likely to list on the ASX on December 9. This is the fourth listing date for the company which issued a replacement prospectus following an unsuccessful attempt to list on the ASX in August.
Former Fauldings exec takes helm at Biota
02 December, 2005 by Ruth BeranPeter Cook is Biota Holdings' (ASX:BTA) new CEO and managing director, starting next Friday.
Neuren raises $6.4m in share placement
02 December, 2005 by Helen SchullerAuckland biopharma Neuren Pharmaceuticals (ASX: NEU) has raised AUD$6.36 million to fund the acceleration of the clinical trial program for Glypromate and NNZ-2566.
Psivida launches food technology spinout
01 December, 2005 by Ruth BeranPerth-based bio-nanotech company Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has created a new spinout company, PsiNutria, to develop its silicon technology in the food industry.
